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Enhancers provide critical information directing cell-
type-specific transcriptional programs, regulated by
binding of signal-dependent transcription factors
and their associated cofactors. Here, we report that
the most strongly activated estrogen (E2)-responsive
enhancers are characterized by trans-recruitment
and in situ assembly of a large 1–2 MDa complex of
diverse DNA-binding transcription factors by ERa
at ERE-containing enhancers. We refer to enhancers
recruiting these factors as mega transcription factor-
bound in trans (MegaTrans) enhancers. The Mega-
Trans complex is a signature of the most potent
functional enhancers and is required for activation
of enhancer RNA transcription and recruitment of co-
activators, including p300 andMed1. TheMegaTrans
complex functions, in part, by recruiting specific
enzymatic machinery, exemplified by DNA-depen-
dent protein kinase. Thus,MegaTrans-containing en-
hancers represent a cohort of functional enhancers
that mediate a broad and important transcriptional
program and provide a molecular explanation for
transcription factor clustering and hotspots noted
in the genome.INTRODUCTION
Functional specialization and precise patterning of different cell
and tissue types are vital for all metazoans, which also generate
cell- or tissue-specific gene expression patterns. Enhancers,
initially defined as DNA elements that act over a distance to posi-
tively regulate expression of protein-encoding target genes, are
the principle regulatory components of the genome that enable
such cell-type-specific and signal-dependent patterns of gene
expression (Banerji et al., 1981; Shlyueva et al., 2014). Each
cell type harbors more than 100,000 candidate enhancers in358 Cell 159, 358–373, October 9, 2014 ª2014 Elsevier Inc.humans, vastly outnumbering protein-coding genes (Bernstein
et al., 2012; Heintzman et al., 2009; Shlyueva et al., 2014). This
makes it very important to be able to predict and understand
which enhancers are actually functionally required for target
coding gene transcriptional regulation.
Enhancer activation requires the presence of specific recogni-
tion sequences for the cooperative recruitment of DNA-binding
transcription factors (TFs) and their cofactors that initially acti-
vate gene expression (Rosenfeld et al., 2006). While the role of
a large number of coactivator complexes and their associated
enzymatic activities is well established (Rosenfeld et al., 2006),
the precise biochemical mechanisms by which so many coacti-
vators are recruited and required for the different functional
activities at specific enhancer sites remain incompletely under-
stood. Global genomic technologies have uncovered character-
istic markers of enhancers and have provided clues as to their
activation. Features that have been used to predict enhancers
that are likely to be functional include the levels of enhancer
RNAs (eRNAs) transcribed from enhancer-like regions in the
genome (Li et al., 2013), the presence of the histone acetyltrans-
ferase p300/CBP (Visel et al., 2009), the timing of RNA Pol II oc-
cupancy (Bonn et al., 2012), and levels of H3K4me2 and
H3K27Ac (Chepelev et al., 2012; Heintzman et al., 2009). How-
ever, because enhancers identified using these features are
not equally functional, additional methods are needed to distin-
guish the enhancers with different activation potential.
There are 2,600 DNA-binding TFs encoded by the human
genome (Babu et al., 2004), with200–300 TFs being expressed
in each cell type (Vaquerizas et al., 2009). A long-standing ques-
tion is how different TFs collaborate to regulate the enhancer
network in a specific cell type. With the large expansion of
genome-wide binding data, DNA-binding transcription factors
were noted to co-bind to some so-called ‘‘hotspot’’ regions or
to cooperatively cluster to some functional enhancers in various
organisms or cell lines (Junion et al., 2012; Rada-Iglesias et al.,
2012; Siersbæk et al., 2014a, 2014b; Wilson et al., 2010; Yan
et al., 2013). However, the underlying mechanism(s) and func-
tional significance of this phenomenon are not well understood.
Recently, the idea of clustered enhancers associated with crit-
ical developmental or cancer-associated transcription units has
been proposed (Hnisz et al., 2013; Love´n et al., 2013;Whyte et al.,
2013). The initial definition of this super-enhancer model was
described as clusters of enhancers spanning >8–10 kb, occupied
by critical DNA-binding transcription factors at their cognate
bindingmotifs (Love´n et al., 2013;Whyte et al., 2013). These clus-
tered super-enhancers control key coding transcription units in
stem cells or various disease states and exhibit high levels of co-
activators, which are suggested to contribute to gene activation.
Cancer cells were also noted to acquire super-enhancers regu-
lating oncogene drivers (Hnisz et al., 2013; Love´n et al., 2013).
While the super-enhancer model can explain the higher expres-
sion levels for a small number of genes in some environments,
it also highlights the need for exploring the functional activities
of single enhancers in the regulation of coding genes critical for
development and disease and understanding the phenomenon
of TF clustering in short-range genomic regions.
Here, we report a signature of the functionally active estrogen-
regulated enhancers, particularly the 1,333 most active ERa en-
hancers linked to target coding gene activation. This signature is
the selective recruitment in trans of an apparent complex of other
DNA-binding TFs, including RARa/g, GATA3, AP2g, STAT1,
AP1, and FoxA1. By gel filtration, we found these TFs migrated
with ERa as a 1–2 MDa complex(es), referred to as the Mega-
Trans complex. The MegaTrans complex is almost invariably re-
cruited to functional ERa-bound enhancers, 22% of which fit
the criteria of being components of super-enhancers. Further-
more, the MegaTrans complex is required for activation of the
functional enhancers, apparently based in part on specific
recruitment of enzymes. This is exemplified by the functionally
important recruitment of the DNA-dependent protein kinase to
ERa-regulated enhancers by RARs. The MegaTrans complex,
in turn, is also required for activation of eRNA transcription and
recruitment of coactivators, including p300 and Med1, and
thus exerts critical biological functions, conceptually parallel to
what has been proposed for super-enhancers.
RESULTS
trans-Bound RARs on ERa Active Enhancers Regulate
ERa Enhancer Function
ERa functions as a central transcription factor for gene programs
that mediate cell growth and proliferation, and it accomplishes
this role primarily through enhancer regulation. Among the total
7,174 ERa-bound enhancers, a subset of 1,333 enhancers
that are located in proximity (<200 kb) to their regulated coding
transcription units have proved to be the most significantly acti-
vated upon estrogen stimulation according to levels of H3K27Ac
and increased eRNA transcription and appear to constitute the
most potent functional enhancer program (Li et al., 2013).
Our current study was initiated by investigating the possible
functional mechanisms by which RARs on retinoic acid response
element (RARE)-containing enhancers mediate RA-induced cod-
ing gene transcriptional programs, as well as the functional role(s)
of RAR at enhancers that accommodate the effects of other sig-
nals, such as E2-induced coding gene transcriptional programs
(Hua et al., 2009; Ross-Innes et al., 2010). To distinguish the
possible binding in cis (the chromatin association of a transcrip-
tion factor through direct DNA binding at its recognition sites)and in trans (the chromatin association of a transcription factor
through protein-protein interaction) functional models of RAR,
we engineered MCF7 to express a bacterial biotin ligase (BirA)
that can biotinylate a biotin ligase recognition peptide (BLRP)-
tagged protein in vivo (Figure S1A available online). Under control
of a Tet-On promoter, wild-type RAR and two DNA-binding
domain mutants that cannot bind to RARE DNA sites (Figures
S1BandS1C)were expressedat similar levels as the endogenous
proteins upon doxycycline induction (Figure S1D). Using these
lines, we first performed biotin chromatin immunoprecipitation
sequencing (ChIP-seq) for wild-type (WT) and mutant RARa/g
(RARb is not expressed in MCF7 breast cancer cells) upon RA
and E2 stimulation. Comparing wild-type and non-DNA-binding
mutants, we found that 15,000/18,000 of WT RARa/g-bound
sites required the intact RARDNA-binding ability because binding
was lost with mutant RARs, and none of these sites were bound
by ERa (Figures S1E–S1G). Among these 15,000 sites, 3,540
were enhancers that exhibited RA activation (Figure S1E), exem-
plifiedby the700most activeRAR cis-binding enhancers,which
showed significant RA-induced eRNA and gene target activation
by global run-on sequencing (GRO-seq) (Figure S1H).
However, there were3,000 RARa/g binding sites that did not
depend on RAR DNA-binding ability (Figures S1E and S2A).
Remarkably, we found that both RARa and RARgwere recruited
to virtually all of the ERa-bound 1,333 active enhancers in
response to E2 (Figure 1A). This observation is consistent with
previous evidence that RAR can bind to ERa binding sites,
although conflicting conclusions were reached regarding its acti-
vating or repressive effects (Hua et al., 2009; Ross-Innes et al.,
2010). However, ERa did not exhibit colocalization with RARs
on ERa non-active enhancers (Figure 1B). By comparing the
binding patterns of wild-type and two non-DNA-binding mu-
tants, we found the binding of RARs on the 1,333 ERa active
enhancers was in trans (Figures 1C and S2A).
Knockdown of either RARa or RARg caused a significant
decrease in both E2-dependent induction of eRNAs and activa-
tion of target coding genes, while knockdown of both caused
almost complete inhibition, as assessed by quantitative PCR
(qPCR) of targets such as GREB1 and TFF1 (Figure 1D). The
knockdown of RARa and RARg, which was confirmed for both
RNA and protein levels (Figures S2B and S2C), inhibited RA
induction of theHoxA1 gene target as expected (Figure 1E). Box-
plot analysis of the GRO-seq experiments showed that the pres-
ence of RARs was required for effective induction of both eRNAs
and target coding gene transcription units upon E2 treatment
(Figures 1F and S2D). RARa/g knockdown also inhibited clas-
sical RAR cis-bound enhancers and their target genes (Figures
S1H and S2E). Thus, while RAR binding in cis activates a distinct
RA-responsive transcriptional program, its recruitment in trans
is also required for effective E2-dependent activation of ERa-
bound functional enhancers.
Next, we utilized wild-type and pBoxmutant RARg to test their
ability to rescue ERa-regulated enhancer function following
endogenous RARg knockdown (Figure S2F). Intriguingly, the
non-DNA-bindingmutant receptor continued to be effectively re-
cruited to the ERa-bound regulatory enhancers at the GREB1
gene (Figure S2A) and was capable of restoring full E2-depen-
dent GREB1 gene activation in rescue experiments (Figure 1G).Cell 159, 358–373, October 9, 2014 ª2014 Elsevier Inc. 359
(legend on next page)
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However, as expected, it failed to activate the cis-bound, RAR-
regulated HoxA1 gene (Figure 1G).
Administration of ICI 182780 to knockdown ERa caused a loss
of RAR binding at the ERa-regulated enhancers (Figures 2D, S3C,
and S3D), but did not alter the binding of RARa or RARg at acti-
vated enhancers harboring cisRARbinding sites (data not shown).
Knockdown of RAR did not cause downregulation of ERa RNA or
protein levels (Figures S2B and S2C) and did not affect the ERa
binding pattern on ERa active enhancers (Figure 1H).
Collectively, our data indicate that ERa selectively recruits
RARa and RARg in trans on the functional enhancers regulating
the most robustly activated target coding genes and that this
strong activation depends on the ERa-mediated trans-binding
of RARs.
ERa Recruits a Mega DNA-Binding Transcription Factor
Complex In Situ at Functional ERa Enhancers
These findings prompted us to examine the behavior of addi-
tional DNA-binding TFs associated with ERa, based on previ-
ously reported mass spectrometry analysis of proteins that
coimmunoprecipitated with ERa (Mohammed et al., 2013) as
well as our own confirmatory data. From these ERa complex
data, we noted a number of DNA-binding transcription factors
associated with ERa, including RARg, GATA3, AP2g, STAT1,
and, intriguingly, FoxA1. To complement these observations,
we also examined the proteins associated with RAR following
pull down from MCF7 cells stably expressing, at physiological
levels, biotin-tagged RARa (Figures S1D and S3A). In addition
to RARa, RXRs, and many well-known cofactors for nuclear
receptors, GATA3was also detected alongwith other DNA-bind-
ing proteins including AP2g, STAT1, c-Fos, and FoxA1 (Fig-
ure 2A). We then performed gel filtration analysis on nuclear
extracts prepared from MCF7 cells in the absence of DNase
treatment and analyzed all fractions for ERa, RARa/g, GATA3,
and the other DNA-binding transcription factors identified in the
mass spectrometry analysis. This analysis revealed co-elution
of ERa, RARa, RARg, GATA3, AP2g, FoxA1, STAT1, c-Fos, and
other proteins in an estimated 1–2 MDa complex(es) (Figure 2B).
These components were all present in ERa-immunoprecipitates
from nuclear extracts and their association was enhanced upon
E2 treatment (Figure S3B). Importantly, knockdown of nuclear
ERa by administration of ICI 182780 caused a virtual loss of
the entire complex associated with ERa by gel filtration analysisFigure 1. trans-Bound RARs on ERa Active Enhancers Regulate E2-Lig
(A) Heatmaps of GRO-seq and ChIP-seq data (±E2) for 1,333 ERa active enhance
both RARa and RARg, respectively.
(B) Heatmaps of GRO-seq and ChIP-seq for a control group of ERa non-active
transcription.
(C) For the 1,333 ERa active enhancers, heatmaps of ChIP-seq data for the wild
association with these enhancers is DNA binding independent.
(D) Knockdown of either RARa or RARg by shRNA inhibits ERa target gene indu
(E) Knockdown of either RARa or RARg using shRNA inhibits expression of the RAR
(F) RARs are required for the E2-liganded activation of ERa active enhancers and t
for either ERa non-active enhancers or non-ERa enhancers.
(G) The pBoxmutant RARg fails to rescue expression of its cis-binding targetHoxA
mutant RARg can rescue expression of the trans-binding target GREB1. For det
(H) Heatmap showing that knockdown of RARs does not affect ERa binding at t
Data are represented as mean ± SEM. NS, not significant. **p < 0.01, ***p < 0.00(Figures 2C and S3C) and recruitment of each factor to ERa-
bound functional enhancers (Figures 2D and S3D). Thus, the
material co-migrating in the gel filtration represented proteins in-
teracting as a complex with ERa rather than artifacts. This com-
plex remained intact in the presence of 250 mM NaCl, but was
lost under 600 mM NaCl high-salt conditions (data not shown).
To further investigate the hypothesis that the ERa-dependent
trans-recruitment/assembly of other DNA-binding transcription
factors occurs only in situ at ERa active enhancers, we first
confirmed that the interactions between ERa and the TFs were
dependent on DNA (Figure S3E). Using a non-DNA-binding
ERa pBox mutant, which is incapable of binding the estrogen
response element (ERE) motif (Stender et al., 2010), we could
show that this mutation abolished the interactions of ERa and
these associated TFs (Figure 2E). As a control, a comparable
RARa pBox mutant did not affect its interaction with ERa and
these TFs (Figure 2F). These data suggest that RARa and other
TFs are recruited by ERE-bound ERa to its activated enhancers;
thus, the entire complex is assembled in situ on ERa-bound
enhancers.
To further confirm that these factors were, indeed, co-recruited
to the same transcription units, rather than the consequence of
differential recruitment behavior in different cell populations, we
performed serial pairwise two-step ChIP analyses to assess the
co-recruitment of RARa with ERa, GATA3, FoxA1, AP2g, and
STAT1 on the same ERa-bound enhancers. Using a BLRP-
tagged RARa stable cell line, two-step ChIP was performed
with biotin-streptavidin pull-down of RARa in the first round
followed by immunoprecipitation with antibodies for RARa (as
positive control), ERa, GATA3, FoxA1, AP2g, and STAT1. In
each case, we found that these proteins were present on the
interrogated active enhancers, including the GREB1 enhancer
(Figure 2G). In contrast, as a control, this was not the case for
the RAR cis-bound enhancer regulating the HoxA1 transcription
unit (Figure 2H). Thus, the MegaTrans complex was co-recruited
to ERa-bound active enhancers but not to functional enhancers
that directly bind RARa in cis. RARa and the other TFs also
were not present at ERa-bound, non-active enhancers (Fig-
ure 2I). Double-ChIP experiments performedwith a BLRP-tagged
GATA3 stable line similarly demonstrated the co-binding of
GATA3 with ERa and all of the other TFs at ERa active enhancers
but not at either the HoxA1 enhancer or ERa non-active en-
hancers (Figure S3F). Together, these data indicate that a featureanded Transcription Activation
rs showing strong E2-induced eRNA transcription and E2-enhanced binding of
enhancers exhibiting no RARa/g binding and no significant E2-induced eRNA
-type and two DNA-binding mutants of RARa/g (+RA and E2) show that their
ction by E2, as demonstrated by qPCR analysis.
cis-binding targetHoxA1 gene in response to RA, as shown by qPCR analysis.
heir targets, as shown by GRO-seq boxplots. No significant effects were found
1 after knockdown of endogenous RARg. In contrast, both wild-type and pBox
ails regarding rescue experiments see Extended Experimental Procedures.
he 1,333 active enhancers.
1. See also Figures S1 and S2.
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Figure 2. ERa Interacts with a Mega Complex of DNA-Binding Transcription Factors at ERE-Containing Active Enhancers
(A) RARa associates with several DNA-binding TFs, as shown bymass spectrometry analysis after pull down of biotin-tagged RARa and elution with TEV protease
digestion. The same inducible BLRP-tagged RARa stable cell line without doxycycline induction was used as a control.
(B) Western blots of gel filtration samples from MCF7 nuclear lysates (+E2) show various DNA-binding TFs associate with ERa in 1–2 MDa fractions.
(C) Knockdown of ERa by ICI 182780 causes loss of the DNA-binding TFs in 1–2 MDa ERa-containing complex, as revealed by immunoblotting of gel filtration
fractions from the 1–2 MDa range (fractions 7, 9, and 11).
(D) DNA-binding TFs in the ERa complex bind to an ERa active enhancer at TFF1 locus upon E2 signal, and knockdown of ERa reduces their binding. ChIP signals
are presented as percentage of input.
(legend continued on next page)
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of the active, regulatory ERa-bound enhancers, in addition to
their increased levels of eRNA transcription, is the selective
recruitment of this MegaTrans complex.
trans-Bound GATA3 Also Regulates Functional
ERa Enhancers
To explore the possible functional consequences of the addi-
tional ERa-interacting transcription factors, we next explored
the potential recruitment and function of GATA3 on ERa active
and non-active enhancers. ChIP-seq experiments revealed, as
in the case of RARa and RARg, that GATA3 was recruited in an
E2-dependent fashion to active enhancers (Figure 3A) but not
non-active enhancers (Figure 3B). Because we found the pres-
ence of GATA3 on functional ERa-bound enhancers that did
not harbor apparent GATA3 cis-binding elements by motif anal-
ysis, we again assessed the possibility that GATA3was recruited
in trans to these ERa-bound active enhancers. Knockdown of
ERa by administration of ICI 182780 inhibitedGATA3 recruitment
to ERa active enhancers (Figures 2D and S3D). Because direct or
indirect ERa and GATA3 interactions were suggested by immu-
noprecipitation experiments (Figure S3B), we investigated the
consequences of disrupting the ability of GATA3 to bind to
cognate DNA sites by two different mutations of the second
zinc finger that is required for cis-binding of GATA3 (Nesbit
et al., 2004) (Figure S4A). We generated inducible BLRP-tagged
stable lines expressing wild-type and the two DNA-binding mu-
tants at physiological levels (Figure S4B), and biotin ChIP-seq re-
vealed they were equivalently recruited, apparently in trans, to
these ERa-bound active enhancers (Figures 3B and S4C). By
comparing the ChIP-seq data for wild-type and DNA-binding
mutants, we found that among 18,000 wild-type GATA3 bind-
ing peaks 5,000 were retained in the two GATA3 mutants, and
these trans-binding sites featured ERE as the topmotif by Homer
analysis (Figure S4D). For the 13,000 cis-binding peaks, GATA
motifs were enriched and a heatmap of the non-ERa enhancers
containing a GATAmotif was used to confirm a total loss of bind-
ing of the two non-DNA-binding GATA3mutants (Figures 3C and
S4D).
Using qPCRs or GRO-seq analysis, we explored the conse-
quences of specific siRNA-mediated knockdown of GATA3 on
E2-dependent induction of eRNAs. We found a dramatic inhibi-
tion of the eRNA activation events on active enhancers (Figures
3D, 3E, and S4E) but no effect on ERa-bound non-active en-
hancers or non-ERa-bound enhancers (Figure 3E). The same in-
hibition effects were also found for gene body expression of the
targets of these 1,333 ERa active enhancers (Figures 3D, 3E, and
S4E). Knockdown of GATA3 did not affect ERa gene expression
at either the RNA or protein level (Figures S4F and S4G) or ERa
binding at active enhancers (Figure 3F). Thus, GATA3 and RARs,
as components of a complex of DNA-binding TFs associated in(E) The interaction of ERa with other DNA-binding TFs is dependent on its DNA-b
pBox mutant ERa. The asterisk marks BLRP-tagged ERa, and the arrow marks
(F) The interaction of RARa with other DNA-binding TFs is independent of its DN
WT or pBox mutant RARa and other TFs. The asterisk marks BLRP-tagged RAR
(G–I) ChIP-reChIP analysis confirms the co-binding of RARa, ERa, and other DNA-
or RAR-bound HoxA1 enhancer. ChIP signals are presented as percentage of in
Data are represented as mean ± SEM. NS, not significant. *p < 0.05, **p < 0.01,trans with ERa on active enhancers, are required for E2-depen-
dent enhancer activation.
ERa Active Enhancers Are Regulated by the
MegaTrans Complex
We next investigated whether other DNA-binding transcription
factors in the MegaTrans complex co-migrating with ERa were
also recruited to E2-actived enhancers even in the absence of
their cognate DNA-binding elements. We reviewed our own
and published ChIP-seq data from MCF7 cells for other DNA-
binding TFs present in the MegaTrans complex (Joseph et al.,
2010; Theodorou et al., 2013). E2-regulated active enhancers
were found to harbor AP2g, FoxA1, c-Jun, and c-Fos, along with
RARa/g and GATA3 (Figures 4A and 4B), but these TFs were not
present on non-active enhancers (Figures 4A and S5A). Similar
to RARa/g and GATA3, the recruitment of the other TFs was
also increased by E2 and abolished by knockdown of nuclear
ERa using ICI 182780 (Figures 4C, 2D, and S3D).
In order to investigate whether, in fact, all DNA-binding
transcription factors present in the MegaTrans complex were re-
cruited in trans to ERa functional enhancers, a series ofDNA-bind-
ing domainmutationswere generated for AP2g, c-Fos, c-Jun, and
STAT1. ChIP-qPCR data on the GREB1 and TFF1 enhancers
showed that the binding of the non-DNA-bindingmutants at these
two ERa active enhancers was comparable to that of the wild-
type proteins (Figure 4D), which confirms the trans-recruitment
of these TFs by ERa.
Based on the roles of RARs and GATA3 on ERa active en-
hancers, we evaluated the functional effects of other recruited
transcription factors. Beginning with AP2g, we found that, in
addition to its recruitment in response to E2 on ERa regulatory
enhancers (Figure 4C), knockdown of AP2g caused a dramatic
inhibition of eRNA and target coding gene expression, as
assayed by both qPCR and GRO-seq (Figures 4E, S5B, and
S5C). Similarly, as STAT1 was also recruited to ERa-bound
enhancers (Figures 2D and S3D), we evaluated its effect on
two well-described ERa bound/regulated enhancers. Again,
we found a functional contribution to the outcome of E2-induced
activation of enhancer transcription and target coding gene
expression (Figure 4F). The same regulatory effects were also
demonstrated upon knockdown of two AP1 components, c-
Jun and c-Fos (Figures S5D and S5E), that were present in the
MegaTrans complex (Figures 4A and 4B).
To begin to assess the interdependency of the components of
the MegaTrans complex on recruitment to ERa-bound functional
enhancers, we tested the consequences of knockdown of
RARa/g, GATA3, and AP2g on GREB1 and TFF1 enhancer
occupancy. We found a marked inhibition of recruitment of
other MegaTrans components upon knockdown of RARa/g
and GATA3 (Figures 4G and 4H) but not by knockdown of AP2ginding ability, as shown by coimmunoprecipitation using BLRP-tagged WT or
endogenous ERa.
A-binding ability, as demonstrated by coimmunoprecipitation of BLRP-tagged
a, and the arrow marks endogenous RARa.
binding TFs on ERa active enhancers but not on the ERa non-active enhancers
put and are compared to negative controls.
***p < 0.001. See also Figure S3.
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Figure 3. trans-Bound GATA3 on ERa Active Enhancers Regulates ERa E2-Liganded Transcription Activation
(A) Heatmap displaying GATA3 binding at the 1,333 ERa active enhancers is enhanced by E2.
(B) Heatmaps of ChIP-seq data for wild-type and two DNA-binding mutants of GATA3 (+E2) show the binding of GATA3 to these ERa active enhancers is not
dependent on its DNA-binding ability. There is no binding of either wild-type or mutant GATA3 to ERa non-active enhancers.
(C) Heatmap of ChIP-seq data for wild-type and two DNA-binding mutants of GATA3 (+E2) shows the binding of GATA3 to these non-ERa enhancers that contain
the GATA motif requires its DNA-binding ability.
(legend continued on next page)
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(Figure 4I), consistent with interdependency of at least some
components of the complex for recruitment of other compo-
nents. RARa/g and GATA3 may serve as key functional compo-
nents, along with ERa, in recruitment/assembly of the Mega-
Trans complex on functional ERa-bound enhancers.
FoxA1 Is Required for ERa Recruitment and MegaTrans
Complex Stabilization on ERa Active Enhancers
These experiments raised a question about potential differences
in DNA sequence features between ERa active enhancers that
bound the MegaTrans complex and ERa non-active enhancers
that did not. Comparison of the EREs between these two groups
revealed that its frequency and the primary consensus se-
quences were essentially identical (Figure 5A). In contrast, and
in accord with the well-known importance of FoxA1 as a pioneer
factor for ERa binding (Hurtado et al., 2011), we noted that the
functional, MegaTrans-bound 1,333 ERa active enhancers
generally harbor a FoxA1 binding motif within 200 bp of the
ERE sites, while the FoxA1 motif was virtually absent on the
nonfunctional, non-MegaTrans-bound ERa enhancers (Fig-
ure 5B). Indeed, the affinity for ERa is >90% lower on the
nonfunctional than functional ERa-bound enhancers (Figure 5C).
Consistent with FoxA1 functioning as a key determinant of ERa
binding (Hurtado et al., 2011), our data showed greatly reduced
binding of ERa at the 1,333 ERa-bound active enhancers upon
FoxA1 knockdown (Figure 5D).
Because FoxA1 appears to be a component of the MegaTrans
complex based on gel filtration and coimmunoprecipitation (co-
IP) data (Figures 2B and S3B) and also exhibits E2-induced bind-
ing at the 1,333 ERa active enhancers (Figure 5E), we speculate
that FoxA1 potentially plays dual roles in the binding of ERa to
functional enhancers and in ERa-dependent recruitment of the
MegaTrans complex. Indeed, knockdown of FoxA1 caused a
dramatic impairment of ERa binding on the functional ERa en-
hancers (Figure 5D), which was accompanied by a loss of
recruitment of the MegaTrans complex on this functional
enhancer cohort (Figure 5F) and inhibition of both eRNA and
gene body activation (Figure 5G). Thus, FoxA1 is distinct from
the other DNA-binding TFs in the MegaTrans complex that
apparently do not affect ERa binding upon knockdown (Figures
1H and 3F).
Roles of MegaTrans Complex in Coactivator
Recruitment and in Super-Enhancer Function
A basic aspect of the mechanism by which MegaTrans compo-
nents function is their requirement for effective activation of E2-
induced eRNAs on the functional enhancers. Accordingly, we
assessed the recruitment of the coactivator p300 by qPCR and
ChIP-seq upon knockdown of RARa/g or GATA3. All of these
knockdowns inhibited the E2-induced accumulation of p300 on
activated enhancers (Figures 6A–6C, and S6A), consistent with
a previous report of a role for RARa in p300 recruitment (Ross-In-(D) Knockdown ofGATA3 affects ERa-dependent activation of eRNA transcriptio
on three independent qPCR experiments (**p < 0.01).
(E) GRO-seq boxplots showing that GATA3 is required for the E2-liganded activa
(F) Heatmap showing that knockdown of GATA3 does not affect ERa binding at
See also Figure S4.nes et al., 2010). Based on the importance of Mediator complex
for enhancer function, putatively due to its roles in enhancer:pro-
moter looping events (Kagey et al., 2010), we also evaluated the
effects of RARa/g and GATA3 knockdown on E2-dependent
recruitment of Med1 to functional enhancers by qPCR, finding
a dramatic inhibition following these knockdowns (Figures 6A
and 6B). This result was confirmed genome-wide by ChIP-seq
(Figures 6D and S6B).
Based on the criteria developed in the initial description of su-
per-enhancers (Hnisz et al., 2013; Whyte et al., 2013), we as-
sessed the number of super-enhancers in MCF7 cells by Med1
ChIP-seq under both –E2 and +E2 conditions. While there are
only 122 super-enhancers under the –E2 condition, E2 treat-
ment increases the total to 320 such enhancers (Figure 6E),
of which 212 contained at least one ERa-bound functional
enhancer, including one at the c-Myc gene locus (Figure S6C).
Thus, only 300 of the 1,333 ERa-bound functional enhancers
characterized by MegaTrans complex fulfill the current definition
of being located in super-enhancers. The efficacy of this subset
of 300 ERa-bound active enhancers was only slightly better than
the other 1,033 ERa-bound active enhancers with respect to
eRNA induction (Figure 6F). Thus, the functional strength of the
ERa-bound enhancers, irrespective of their presence in a su-
per-enhancer, is predicted by the presence of the MegaTrans
complex.
Actually, for the 212 super-enhancers that contain ERa active
enhancers, their Med1 levels were also dependent on the E2
signal (Figure S6C). Interestingly, we observed greatly reduced
levels of Med1 at these 212 super-enhancers following knock-
down of RARs (Figure 6G), suggesting that MegaTrans en-
hancers are important constituents in the function of these clus-
tered super-enhancers.
DNA-Binding TFs of the MegaTrans Complex Might
Recruit Specific Functionally Required Components for
Enhancer Activation
Based on the presence of specific non-transcription factor com-
ponents in the mass spectrometry analysis of RARa-associated
proteins (Figure 2A), we evaluated the functional significance of
these additional proteins. We elected to focus on DNA-depen-
dent protein kinase (DNA-PK), comprising the catalytic subunit
DNA-PKcs, Ku70, and Ku80, because all three DNA-PK subunits
were present in the RARa pull down as revealed by mass spec-
trometry.We confirmed these associations by co-IP andwestern
blot analysis (Figure 7A). DNA-PKcs has previously been re-
ported as a component of the ERa complex that directly phos-
phorylates S118 of ERa (Foulds et al., 2013), and we confirmed
that knockdown of DNA-PKcs partially impacted phosphoryla-
tion of ERa S118 without affecting ERa binding at ERa active en-
hancers (Figure 7B). Using a specific antibody against DNA-
PKcs for ChIP analysis, we first evaluated the temporal kinetics
of its potential recruitment on the GREB1 and TFF1 enhancers,n and coding gene expression forGREB1 and TFF1 genes. Mean ± SEM based
tion of ERa active enhancers and their coding gene targets.
the 1,333 active enhancers.
Cell 159, 358–373, October 9, 2014 ª2014 Elsevier Inc. 365
Figure 4. ERa Active Enhancers Are MegaTrans Enhancers Regulated by DNA-Binding TFs
(A) Heatmaps of ChIP-seq data for different TFs (+E2) displaying strong binding of these DNA-binding TFs at the 1,333 ERa active enhancers but not at ERa
non-active enhancers.
(legend continued on next page)
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finding recruitment at 10 min following E2 treatment of MCF7
cells (Figure 7C). In addition, a specific antibody against phos-
phorylated ERa S118 revealed strong enrichment that peaked
at 20 min, slightly after the recruitment of ERa and DNA-PKcs
(Figure 7C). Based on these observations, we conducted ChIP-
seq analysis of DNA-PKcs in MCF7 cells after 10 min of E2 treat-
ment, which revealed 12,629 peaks that mostly located in inter-
genic regions (Figure S7A). Of the detected peaks, 971 were on
the ERa-bound, MegaTrans-containing active enhancers but
few were present on non-active enhancers (Figures 7D and
S7B). A second antibody for DNA-PKcs yielded similar ChIP-
seq results, confirming the specificity of the signal (data not
shown).
In order to determine whether trans-bound RAR is required
for the recruitment of DNA-PKcs at ERa active enhancers, we
performed ChIPs for both DNA-PKcs and pERaS118 after
knockdown of RARa/g. We found that RARa/g knockdown
substantially reduced the levels of both DNA-PKcs and pE-
RaS118 at ERa active enhancers (Figures 7E–7G, S7C, and
S7D), suggesting that trans-bound RARs may be required for
the functionally relevant recruitment of DNA-PKcs at these
ERa enhancers.
Knockdown of DNA-PKcs significantly inhibited E2-induced
activation of ERa-bound functional enhancers and their target
coding gene expression but did not affect RA-induced HoxA1
activation (Figure 7H). Consistently, the treatment of MCF7 cells
with the DNA-PK kinase inhibitor NU7441 also inhibited ERa-d-
ependent target activation (Figure S7E). Thus, at least one role
of RARs that are recruited to ERa-bound functional enhancers
may be to facilitate the concomitant recruitment of a specific
protein kinase. It is possible that, analogous to this role of
RARs in recruitment of DNA-PK, other DNA-binding TFs compo-
nents in the MegaTrans complex also contribute to the recruit-
ment of additional enzymatic factors that are required for func-
tional enhancer activation.
DISCUSSION
The MegaTrans Complex Is a Signature of ERa
Functional Enhancers
Here, we suggest that, in addition to the critical recruitment of an
ever-increasing number of well-characterized coactivator com-
plexes, many with specific enzymatic functions, activation of
the most robust subset of ERa enhancers by E2 is dependent
upon, and can be predicted by, their ability to recruit a complex
of established DNA-binding transcription factors, referred to as
the MegaTrans complex (Figure 7I). This complex appears to(B) UCSC browser snapshot of an ERa active enhancer for FoxC1, which exemp
(C) Heatmap showing AP2g binding at ERa active enhancers, but not at ERa no
(D) WT and non-DNA-binding mutants of MegaTrans TF components bind equiv
biotin ChIP using BLRP-tagged TFs (GFP served as control). For details regardin
ChIP signals are presented as percentage of input.
(E) GRO-seq boxplots showing that AP2g is required for ligand-dependent activat
(F) STAT1 is required for the activation of ERa active enhancers and coding gene
and qPCR analysis.
(G–I) Knockdown of RARs or GATA3, but not AP2g, greatly reduces the E2-enh
GREB1. ChIP signals are presented as percentage of input.
Data are represented as mean ± SEM. NS, not significant. *p < 0.05, **p < 0.01.be recruited/assembled in trans on ERa-bound functional en-
hancers and requires the presence of ERa. In addition to the
requirement for ERa, certain other components of the complex
appear to be necessary for its assembly on functional enhancers;
for example, knockdown of RARa/g and GATA3 abolishes
recruitment of other components of the complex and inhibits
enhancer/target coding gene activation. Although the precise
biochemical interactions that underlie the formation of theMega-
Trans complex remain incompletely defined, our data on the ef-
fects of DNase I treatment and DNA-binding domain mutation
suggest that the MegaTrans complex assembles in situ at ERa-
bound, ERE-containing enhancers, which also typically harbor
nearby FoxA1 cis-binding sites.
While the idea that DNA-binding transcription factors can be
recruited in trans to either activate or repress specific target
coding genes is well established (Langlais et al., 2012; Pascual
et al., 2005; Reichardt et al., 1998), this study provides an initial
description of a ligand-dependent recruitment in trans of a
complex of DNA-binding transcription factors that proves
important for ERa function. Using the published criteria for
defining super-enhancers (Hnisz et al., 2013; Whyte et al.,
2013), only 22% of the functional MegaTrans enhancers can
be classified as components of super-enhancers, and we
note that there is only a very slight distinction in the levels of
eRNA induction in response to E2 on the functional MegaTrans
enhancers associated with super-enhancers compared to
those not associated with the super-enhancers. Thus, recruit-
ment of the MegaTrans complex serves as a mark that distin-
guishes the most active enhancers of the estrogen-regulated
transcriptional program.
These observations raise several corollary questions. First,
does thisMegaTrans complex serve on all active or activated en-
hancers, irrespective of the DNA-binding transcription factors
bound in cis to those enhancers? It appears that the RARE-con-
taining functional enhancers, which recruit RARa/g in cis, do not
recruit this complex or ERa (Figure S1G). Therefore, we specu-
late that there may be a number of distinct MegaTrans com-
plexes that are recruited only by certain regulatory DNA-binding
factors, and these complexes, analogous to events for ERa-re-
gulated enhancers, serve to mark and initiate other specific
enhancer activation events. Second, how is the MegaTrans
complex selectively recruited only to the functional ERa-bound
enhancers? Based on our initial data, we suggest that the answer
likely involves the apparent dual roles of the ‘‘pioneer factor’’
FoxA1, which is selectively recruited to the functional, Mega-
Trans-dependent enhancers at <200 bp from the ERE but is
also required for the binding of ERa to these enhancers. Inlifies a MegaTrans-bound enhancer (+E2).
n-active enhancers, in response to E2.
alently to two ERa active enhancers of TFF1 and GREB1, as demonstrated by
g DNA-binding domain mutagenesis see Extended Experimental Procedures.
ion of both eRNA and target gene body transcription for ERa active enhancers.
expression by E2 for GREB1 and TFF1 genes, as demonstrated by knockdown
anced occupancy of DNA-binding TFs on ERa active enhancers of TFF1 and
See also Figure S5.
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Figure 5. FoxA1 Performs Dual Roles on
ERa Active Enhancers
(A and B) ERa and FoxA1 motif analyses using
Homer program for 1,333 ERa active enhancers
and ERa non-active enhancers (see Extended
Experimental Procedures for analysis details).
(C) Boxplot based on ERa ChIP-seq data (+E2)
showing higher binding affinity of ERa at 1,333
ERa active enhancers than at ERa non-active
enhancers.
(D) Heatmap showing that knockdown of FoxA1
greatly reduces ERa binding at the 1,333 active
enhancers.
(E) Heatmap showing FoxA1 binding at 1,333 ERa
active, but not at ERa non-active enhancers, is
enhanced in response to E2.
(F) Conventional ChIP assays for TFF1 andGREB1
enhancers showing knockdown of FoxA1 sub-
stantially reduced binding of ERa and the Mega-
Trans components following E2 treatment. ChIP
signals are presented as percentage of input.
(G) FoxA1 is required for the activation of ERa
active enhancers in response to E2, as exemplified
by the effects of FoxA1 knockdown on coding
gene expression and eRNA transcription for
GREB1 and TFF1 genes.
Data are represented as mean ± SEM. *p < 0.05,
**p < 0.01.addition to its established pioneering role, FoxA1 may also make
an important contribution to the recruitment/stabilization of the
MegaTrans complex. We are tempted to speculate that, in addi-
tion to promoting cooperative binding of ERa to enhancers,
FoxA1 may cause a conformational alteration in the ERa recep-
tor, either directly or via altered enhancer DNA architecture, that
facilitates the recruitment of the MegaTrans complex; however,
it is formally possible that the increased affinity of ERa for the
enhancer alone determines binding of the MegaTrans complex.
These questions and other undefined aspects of the MegaTrans
complex represent fascinating issues for future investigation.368 Cell 159, 358–373, October 9, 2014 ª2014 Elsevier Inc.The MegaTrans Complex as a
Platform for Regulatory Enzymes
In light of the already large number of
important coactivator complexes, why
would these additional DNA-binding
transcription factors, most of which are
recruited to the active enhancers by the
ERE-bound ERa, be required? First, we
have found that they play important
‘‘early’’ roles in enhancer function as
they are important for eRNA induction
and the ligand-dependent increase of
p300 and Med1 occupancy on the en-
hancers. Thus, components of the Meg-
aTrans complex are required to license
the recruitment of well-known, important
coactivators, as exemplified by p300
and Mediator subunits. In this regard,
the DNA-binding transcription factors
summoned to bind in trans throughERa are subserving functions that are quite analogous to those
of the recognized coactivator complexes, many of which
feature associated/intrinsic enzymatic activities. Similarly, we
note that RARs are capable of interacting with many known
or potential coactivators, and we have focused on one such
potential regulator. The enzyme DNA-PKcs binds to RARs
and is recruited with rapid temporal kinetics to ERa-bound
functional enhancers. Additionally, knockdown of DNA-PKcs
partially phenocopies the functional consequences of RARa/g
knockdown in MCF7 cells. Therefore, we are tempted to spec-
ulate that components of the MegaTrans complex individually
Figure 6. trans-Bound TFs on MegaTrans Enhancers Are Required for Recruitment of ERa Coactivators and Super-Enhancer Function
(A and B) Knockdown of RARs or GATA3 greatly reduces the E2-enhanced binding of p300 and Med1 to ERa active enhancers. ChIP signals are presented as
percentage of input.
(C) Heatmap and tag density plot of p300 ChIP-seq data for four different conditions demonstrating that knockdown of RARs by shRNA reduces E2-enhanced
p300 recruitment on 1,333 ERa active enhancers.
(D) trans-bound RARs are required for E2-enhanced recruitment of the coactivator Med1 to ERa active enhancers, as shown by a heatmap of Med1 ChIP-seq
data on 1,333 ERa active enhancers.
(E) A Med1 tag density plot based on Med1 ChIP-seq (+E2) data and clustering of enhancers identifies 320 super-enhancers in MCF7 cells (see Extended
Experimental Procedures for analysis details).
(F) A boxplot analysis based on GRO-seq data (+E2) of eRNA expression levels for two groups of ERa active enhancers: the 300 ERa active enhancers located in
super-enhancers (median: 5.14) and 1,033 ERa active enhancers that are not located in super-enhancers (median: 3.59).
(G) Tag density plot showing knockdown of trans-bound RARs, which affects the function of ERa active enhancers, reduces the E2-enhancedMed1 signal at 212
super-enhancers that contain ERa active enhancers.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01. See also Figure S6.recruit various enzymes/factors that collectively are mechanis-
tically important in initial activation of the functional enhancer
program. DNA-PK is a kinase with multiple targets, including
ERa on Ser118 (Foulds et al., 2013), which we find occurs on
the active ERa-bound enhancers, dependent on the presence
of RARs on these functional enhancers. It is particularly
intriguing that DNA-PKcs is associated with the Ku80 complex,classically considered to be involved in DNA damage repair
(Hartley et al., 1995; Jin and Weaver, 1997), which may in
fact be pertinent to its functions in transcriptional control
events. The rapid appearance of DNA-PKcs on the ligand-regu-
lated enhancers is analogous to other examples of recruited
protein kinases in gene regulation events (Perissi et al., 2008;
Tee et al., 2014).Cell 159, 358–373, October 9, 2014 ª2014 Elsevier Inc. 369
(legend on next page)
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Thus, investigation of the ERa-regulated enhancers has re-
vealed that an additional and critical component of the most
active enhancers is the ERa-dependent recruitment of the Meg-
aTrans complex, which promotes combinatorial recruitment of
additional coactivators/enzymes that increase enhancer activa-
tion and target coding gene transcription. Analogous to the hy-
pothesis that super-enhancers regulate critical developmental
or disease-associated coding gene transcriptional programs,
MegaTrans complex recruitment appears to serve as a mecha-
nism of marking/empowering enhancers to control key aspects
of the regulatory transcriptional programs in a specific cell
type. The super-enhancer model defines the combinatorial ef-
fects of multiple, clustered enhancers spanning >8–10 kb, while
the MegaTrans enhancer model explains the differential func-
tional activity of single enhancers.
MegaTrans Enhancers as a Commonly
Utilized Strategy?
The uncovering of another layer ofmachinery involved in the effec-
tive activation of ERa-regulated enhancers raises the possibility
that distinct MegaTrans enhancers exist for other classes of
DNA-binding TFs that are responsible for activation of unique
transcriptional programs. We note that ChIP-seq analyses for
many established DNA-binding TFs have revealed their binding
on enhancers that do not harbor any known cognate binding
sequences. This raises the possibility that these TFs might exert
roles, in trans, on other transcription programs analogous to the
effects of the MegaTrans complex on the ERa-regulated func-
tional enhancers. The ‘‘hotspot’’ or ‘‘clustering’’ phenomenon of
DNA-binding TFs has recently been reported in several different
organisms (Junion et al., 2012; Rada-Iglesias et al., 2012;
Siersbæk et al., 2014a; 2014b; Wilson et al., 2010; Yan et al.,
2013). However, the underlying molecular mechanism(s) and
functional significance are not well understood. Our results
provide a functional model to explain at least many cases of the
clustering phenomena. Specifically, our data suggest that the
DNA-dependent binding of ERa and FoxA1 at ERa functional
enhancers establishes a platform for recruiting a MegaTrans
complex of other DNA-binding TFs by protein-protein interactions
(in trans).MegaTrans complex-bound enhancers function asmoreFigure 7. trans-Bound RAR May Contribute to the Recruitment of DNA
(A) Western blots demonstrating interaction of doxycycline-induced BLRP-RARa
asterisk marks BLRP-tagged RARa, and the arrow marks endogenous RARa.
(B) Conventional ChIP assays for TFF1 and GREB1 enhancers showing DNA-P
presence of S118-phosphorylated ERa (pERaS118). ChIP signals are presented
(C) The kinetics of ERa, DNA-PKcs, and pERaS118 occupancy at ERa active en
(D) Heatmaps, based on ChIP-seq data, showing DNA-PKcs binding at 1,333 ER
non-active enhancers.
(E) Knockdown of RARs by shRNA greatly reduces DNA-PKcs binding to ERa acti
as percentage of input.
(F) Heatmap of DNA-PKcs ChIP-seq data showing loss of E2-enhanced DNA-PK
(G) Heatmap of pERaS118 ChIP-seq data demonstrating partial reduction of E2-e
RARs.
(H) Knockdown of DNA-PKcs by shRNA affects E2-liganded activation of gene bo
levels or RA induction of the HoxA1 gene, as demonstrated by qPCR.
(I) Working model of a MegaTrans enhancer. At ERa active enhancers that con
in situ the functionally required MegaTrans complex of DNA-binding TFs, includi
MegaTrans complex may recruit specific, functional enzymatic machinery, exem
Data are represented as mean ± SEM. NS, not significant. *p < 0.05, **p < 0.01,robust enhancers by recruiting certain unique factors and en-
zymes, such as DNA-PK. Thus, our study provides insights into
understanding the phenomenon of TF clustering. Our data also
simultaneously help to explain why ChIP-seq analyses reveal
50% of the regions occupied by many of the DNA-binding TFs
assayed in the ENCODE project do not harbor cognate DNA-
binding motifs.
EXPERIMENTAL PROCEDURES
A detailed description of all methods and any associated references is pro-
vided in the Extended Experimental Procedures (including Tables S1, S2,
and S3), which can be found in the supplemental data section.
Cell Culture and BLRP-Tagged Stable Cell Lines
MCF7 cells, initially obtained from ATCC, were maintained in culture and
treated as described (Li et al., 2013). To study binding patterns for wild-type
and non-DNA-binding mutants of RARa/g, GATA3, ERa, and other TFs, we
first established a parental MCF7 stable cell line that expressed BirA enzyme
and Tet-Repressor. We then used this parental cell line to make doxycycline-
inducible stable cell lines expressing BLRP-tagged proteins at close to endog-
enous levels. BLRP-tagged proteins were biotinylated in vivo by BirA enzyme,
allowing for pull downs to be performed with NanoLink streptavidin magnetic
beads (Solulink) under very stringent washing conditions.
Chromatin Immunoprecipitation and Global Run-on Sequencing
ChIP-qPCRs, ChIP-seqs, and GRO-seqs were performed as previously re-
ported (Li et al., 2013). Immunoprecipitated DNAwas recovered by purification
on QIAquick spin columns (QIAGEN) after decrosslinking and then analyzed by
qPCR using primers listed in Table S1. The qPCR-validated DNA sampleswere
used to make libraries for deep sequencing. The details of ChIP-seq and GRO-
seq data analysis are included in the Extended Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus databank accession number for all deep
sequencing data reported in this paper is GSE60272, which includes ChIP-
seq data sets (GSE60270) and GRO-seq data sets (GSE60271).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and three tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.08.027.-PK Kinase as a Coactivator for ERa Active Enhancers
protein with DNA-PKcs after pull down by streptavidin magnetic beads. The
Kcs is not required for the occupancy of ERa but is partially required for the
as percentage of input.
hancers. ChIP signals are presented as percentage of input.
a active enhancers is enhanced by E2, while its binding is not apparent at ERa
ve enhancers and affects enrichment of pERaS118. ChIP signals are presented
cs binding to ERa active enhancers upon knockdown of both RARs.
nhanced pERaS118 binding to ERa active enhancers upon knockdown of both
dy and eRNA transcription forGREB1 and TFF1 genes but does not affect ERa
tain ERE and FoxA1 motifs, DNA-bound ERa and FoxA1 dynamically recruit
ng RAR, GATA3, AP2g, STAT1, and AP1. The trans-bound components of the
plified by the recruitment of DNA-PK.
***p < 0.001. See also Figure S7.
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